262 related articles for article (PubMed ID: 6897013)
1. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
2. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer.
Legha SS; Blumenschein GR; Buzdar AU; Hortobagyi GN; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):1961-4. PubMed ID: 526929
[TBL] [Abstract][Full Text] [Related]
4. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
5. m-AMSA: phase II trial in advanced lymphoma and leukemia.
Case DC
Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
8. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Rivera G; Evans WE; Dahl GV; Yee GC; Pratt CB
Cancer Res; 1980 Nov; 40(11):4250-3. PubMed ID: 6258775
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical evaluation of intravenous 4'-(9-acridinylamino)methanesulfon-m-anisidide in colorectal cancer.
Valdivieso M; Stroehlein JR; Bedikian AY; Karlin DA; Legha SS; Bennetts RW; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):39-44. PubMed ID: 6687657
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
Weick JK; Jones SE; Ryan DH
Cancer Treat Rep; 1983 May; 67(5):489-92. PubMed ID: 6687839
[TBL] [Abstract][Full Text] [Related]
13. Phase II study with amsacrines (m-AMSA and m-AMSA lactate) in refractory lymphomas.
Bajetta E; Buzzoni R; Viviani S; Villani F; Piotti P; Gasparini G; Bonadonna G
Cancer Treat Rep; 1985 Sep; 69(9):965-9. PubMed ID: 3839714
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
16. A phase II trial of m-AMSA in patients with small-cell lung cancer.
Natale RB; Gralla RJ; Wittes RE
Cancer Clin Trials; 1981; 4(4):393-5. PubMed ID: 6274533
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
18. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
19. Phase II trial of m-AMSA in hepatocellular carcinoma: a Southwest Oncology Group Study.
Bukowski RM; Legha S; Saiki J; Eyre HJ; O'Bryan R
Cancer Treat Rep; 1982 Aug; 66(8):1651-2. PubMed ID: 6286120
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
[Next] [New Search]